Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2–3 years from tamoxifen to exemestane. This PathIES aimed to assess the role of immunohistochemical (IHC)4 score in determining the relative sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheang, M. C. U., Bliss, J. M., Viale, G., Speirs, V., Palmieri, C., Shaaban, A., Lønning, P. E., Morden, J., Porta, N., Jassem, J., van De Velde, C. J., Rasmussen, B. B., Verhoeven, D., Bartlett, J. M. S., Coombes, R. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847042/
https://www.ncbi.nlm.nih.gov/pubmed/29177605
http://dx.doi.org/10.1007/s10549-017-4543-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847042/
https://www.ncbi.nlm.nih.gov/pubmed/29177605
http://dx.doi.org/10.1007/s10549-017-4543-7

Ejemplares similares